Start: Wednesday, June 5, 2024 - 01:00 pm
Public Notices

North Dakota Medicaid Drug Use Review Board
Wednesday, June 5, 2024
1 p.m. to 4 p.m. Central Time

In-Person Information
Conference Room 210/212, 2nd Floor, Judicial Wing, State Capitol
600 E. Boulevard Ave., Bismarck

Virtual Information
Join virtually: Click here to join the meeting
Join by phone: 701-328-0950, Conference ID: 876 672 920 #

1.    Call to Order
2.    Roll Call
3.    Review and Approval of Minutes
4.    Reports from Department
    •    Administrative Report: Utilization Review  
    •    Financial Report: Top Drugs
    •    Retrospective DUR Report
    •    Clinical Report:  
          o    Prior Authorization Update 
          o    Criteria updates: Food Allergy (Xolair), Peanut Allergy (Palfozia), Reduce Risk of Major Adverse Cardiovascular Events (Wegovy), Pulmonary Hypertension (Wenrevair), Tardive Dyskinesia (Ingrezza, Austedo) 
5.    Special Orders: Presiding Officer and Vice-Presiding Officer Elections
6.    Unfinished Business: Update to Hyperkalemia
7.    New business
    •    Second Review of Acid Blockers (Voquezna)
    •    Second Review of Seborrheic Dermatitis (Zoryve)
    •    Second Review of Primary Hyperoxaluria Type 1 (Rivfloza)
    •    Second Review of Myasthenia Gravis (Zilbrysq)
    •    Second Review of Duchenne Muscular Dystrophy (Emflaza, Agamree)
    •    Second Review of Paroxysmal Nocturnal Hemoglobinuria (Empaveli, Fabhalta)
    •    First Review of Molluscum Cantagiosum (Ycanth and Zelsuvmi)
    •    First Review of Epidermolysis Bullosa (Filsuvez)
    •    First Review of Metabolic Dysfunction–Associated Steatohepatitis (Rezdiffra)
    •    Review of retrospective DUR criteria recommendations
8.    Announcements: Next Meeting (September 4, 2024)
9.    Adjourn

Individuals with disabilities who need accommodations, including appropriate auxiliary aids to participate, can contact Ashley Gerving at 701-328-2354, toll-free 800-755-2604, 711 (TTY) or

Date Posted: Jan. 18, 2024
Date Revised:  April 29, 2024 (agenda/meeting details added)